AQST (Mkap $76 M) 3 Marketed Drugs / 4 NDAs eingereicht (Seite 3)
eröffnet am 09.10.19 18:18:31 von
neuester Beitrag 20.03.24 10:27:43 von
neuester Beitrag 20.03.24 10:27:43 von
Beiträge: 67
ID: 1.313.511
ID: 1.313.511
Aufrufe heute: 0
Gesamt: 9.363
Gesamt: 9.363
Aktive User: 0
ISIN: US03843E1047 · WKN: A2JQ4G · Symbol: AQST
4,3000
USD
+0,47 %
+0,0200 USD
Letzter Kurs 12:42:04 Nasdaq
Neuigkeiten
12.04.24 · globenewswire  |
01.04.24 · globenewswire |
25.03.24 · globenewswire |
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock 20.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +163,57 | |
| 0,5470 | +20,09 | |
| 384,00 | +20,00 | |
| 5,9050 | +17,86 | |
| 111,15 | +16,77 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 71,33 | -33,92 | |
| 3,6400 | -38,62 | |
| 1.160,00 | -42,00 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 62.364.521 von shaxx am 13.01.20 22:15:51
Von mir nur Beileid (habe aber ähnliches im depot....)
Zitat von shaxx: Suche mitleidende. Bitte melden.
Lol. Buy the dip!
Von mir nur Beileid (habe aber ähnliches im depot....)
Suche mitleidende. Bitte melden.
Lol. Buy the dip!
Lol. Buy the dip!
Antwort auf Beitrag Nr.: 62.307.224 von fisch29 am 07.01.20 20:08:34Bin auch noch dabei. Teile Deine Meinung. Erinnert mich an Axsm. Die habe ich leider bei 2 $ verkauft.
Abwarten und Tee trinken. Es stehen ja nich einige Termin in naher Zukunft an. Gruß.
Abwarten und Tee trinken. Es stehen ja nich einige Termin in naher Zukunft an. Gruß.
Antwort auf Beitrag Nr.: 62.127.236 von fisch29 am 10.12.19 22:16:34Ist hier noch jemand dabei? Bin gestern zu 5,65 $ wieder eingestiegen, da hatte ich anscheinend einen guten Riecher. Die Aktie gefällt mir sehr gut, interessante Produkte in der Pipeline, warum sollten hier nicht 10 $ in 2020 möglich sein. Ich denke das die Aktien aus der KE jetzt alle platziert wurden und es nun wieder up gehen kann.
Antwort auf Beitrag Nr.: 62.006.534 von Biohero am 25.11.19 14:33:51Du hattest mal wieder den richtigen Riecher!
WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet patients’ unmet needs and solve therapeutic problems, today announced that it intends to offer and sell $35 million of shares of its common stock in an underwritten public offering. In connection with this offering, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional $5.25 million of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are being offered by Aquestive.
BMO Capital Markets is acting as sole book-running manager for this offering.
Aquestive intends to use the net proceeds of this offering for the continuation of the commercial launch of Sympazan®, preparations to support the expected launch of its product candidate Libervant™ in late 2020 (if approved by the US Food and Drug Administration (the “FDA”)), continued development of AQST-108 and other product candidates, working capital and general corporate purposes.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on September 17, 2019 only by means of a prospectus supplement and accompanying prospectus included in the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.
This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet patients’ unmet needs and solve therapeutic problems, today announced that it intends to offer and sell $35 million of shares of its common stock in an underwritten public offering. In connection with this offering, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional $5.25 million of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are being offered by Aquestive.
BMO Capital Markets is acting as sole book-running manager for this offering.
Aquestive intends to use the net proceeds of this offering for the continuation of the commercial launch of Sympazan®, preparations to support the expected launch of its product candidate Libervant™ in late 2020 (if approved by the US Food and Drug Administration (the “FDA”)), continued development of AQST-108 and other product candidates, working capital and general corporate purposes.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on September 17, 2019 only by means of a prospectus supplement and accompanying prospectus included in the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.
This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Trading Spotlight
Antwort auf Beitrag Nr.: 62.006.534 von Biohero am 25.11.19 14:33:51Danke. Könnte vielleicht so laufen wie bei Eton oder Ardx. Nach Zulassung kommt immer eine Korrektur. Dane und Gruß.
Antwort auf Beitrag Nr.: 62.006.372 von pharma-trader am 25.11.19 14:11:27Würde verkaufen bis das mit dem Cashbestand geklärt ist aber jeder soll machen wie er denkt .
Antwort auf Beitrag Nr.: 62.005.346 von Biohero am 25.11.19 12:04:16Halten oder verkaufen?
# Biohero: wir hoch kann sie heute laufen?
Danke!
# Biohero: wir hoch kann sie heute laufen?
Danke!
Antwort auf Beitrag Nr.: 62.005.190 von pharma-trader am 25.11.19 11:49:22Japp ist bereits Zugelassen ...
https://gmpnews.net/2019/11/fda-approved-aquestive-therapeut…
https://gmpnews.net/2019/11/fda-approved-aquestive-therapeut…
Pre market am 25.11.19
Monn zusammen, In pre schon 21% im plus. Ist schon etwas durchgesickert vom pdufa??
Danke!
Durchsuchen
AQST (Mkap $76 M) 3 Marketed Drugs / 4 NDAs eingereicht
